Showing papers in "Biology of Blood and Marrow Transplantation in 2019"
University of Virginia1, Memorial Sloan Kettering Cancer Center2, Washington University in St. Louis3, Fred Hutchinson Cancer Research Center4, National Institutes of Health5, Harvard University6, Novartis7, Seattle Children's8, University of Pennsylvania9, University College London10, Center for International Blood and Marrow Transplant Research11, University of Miami12, University of Texas MD Anderson Cancer Center13
TL;DR: The goal is to provide a uniform consensus grading system for CRS and neurotoxicity associated with immune effector cell therapies, for use across clinical trials and in the postapproval clinical setting.
1,403 citations
TL;DR: Collaborative efforts are underway to harmonize the definition and grading of CRS to allow for better interpretation of toxicities across CAR-T products and clinical trials and allow for informed management algorithms.
187 citations
Harvard University1, Brigham and Women's Hospital2, Ronald Reagan UCLA Medical Center3, University of Texas MD Anderson Cancer Center4, University of Chicago5, NewYork–Presbyterian Hospital6, Memorial Sloan Kettering Cancer Center7, Durham University8, University of Washington9, Fred Hutchinson Cancer Research Center10
TL;DR: Adult CMV-seropositive HCT recipients without CMV viremia at screening 2:1 to receive brincidofovir or placebo until week 14 post-HCT received anti-CMV treatment, with mixed results.
133 citations
TL;DR: It is found that CPI use both before and after allo-HSCT can be highly effective, but exposure can lead to a significantly increased risk of GVHD-related morbidity and mortality in this patient population.
125 citations
Johns Hopkins University1, Memorial Sloan Kettering Cancer Center2, University of Washington3, University of Texas Southwestern Medical Center4, University of Pennsylvania5, Mayo Clinic6, Alfaisal University7, University of Texas MD Anderson Cancer Center8, Vanderbilt University9, Sheba Medical Center10, Harvard University11, National Marrow Donor Program12, University of Minnesota13, Children's National Medical Center14, Washington University in St. Louis15, Medical College of Wisconsin16, Baylor College of Medicine17, Fred Hutchinson Cancer Research Center18, University of Miami19, Case Western Reserve University20, University of Texas Medical Branch21, University of Paris22, Stanford University23, Vanderbilt University Medical Center24, National Institutes of Health25, Cornell University26
TL;DR: Advice is provided from experts in the fields of hematopoietic cell transplantation, cellular immunotherapy, and lymphoma regarding key clinical questions pertinent to the utilization of CD19 CAR T for the treatment of NHL.
114 citations
TL;DR: The latest studies reporting VOD/SOS risk factors support previously published data, although the importance of patient-related factors, such as acute kidney injury, increased international normalized ratio, female sex (in children), and platelet refractoriness, is given greater emphasis in the recent data.
103 citations
University of Delaware1, Alfred I. duPont Hospital for Children2, Shanghai Jiao Tong University3, University of Manchester4, Tokai University5, University of the Ryukyus6, Memorial Sloan Kettering Cancer Center7, Universidade Federal do Rio Grande do Sul8, Oswaldo Cruz Foundation9, University of Milano-Bicocca10, Shimane University11, Gifu University12
TL;DR: The efficacy, side effects, risks, and cost of HSCT for each type of MPS is summarized.
101 citations
TL;DR: It is suggested that haplo-BMT with post-transplantation cyclophosphamide and thiotepa improves donor engraftment without significantly increasing morbidity or mortality and could dramatically expand curative options for individuals with SCD.
94 citations
University of Texas Southwestern Medical Center1, University of Pennsylvania2, Fred Hutchinson Cancer Research Center3, Vanderbilt University Medical Center4, Center for Cell and Gene Therapy5, Children's National Medical Center6, University of Miami7, Mayo Clinic8, Aix-Marseille University9, Memorial Sloan Kettering Cancer Center10, Ohio State University11, George Washington University12, University of Minnesota13, Vita-Salute San Raffaele University14, Washington University in St. Louis15, University of Texas MD Anderson Cancer Center16, Sheba Medical Center17, National Institutes of Health18, King's College London19, Stanford University20, American University of Beirut21, University of Paris22
TL;DR: An initial roadmap for navigating common clinical practice scenarios that will become more prevalent now that the first commercially available CAR-T product for B-ALL has been approved is presented.
85 citations
TL;DR: HSCT is confirmed as an effective treatment for CALD when performed early, and survival without MFDs is proposed as a relevant treatment goal, rather than solely assessing OS as an indicator of treatment success.
78 citations
TL;DR: Better HLA matching, found when typing is done at UHR that includes exons outside of the ARD, introns, and untranslated regions, can significantly improve outcomes for recipients of a VUD-HCT for a hematologic malignancy and should be prospectively performed at donor selection.
TL;DR: In the absence of an HLA-identical donor, HIFD HSCT with PTCY is a viable option for patients with life-threatening inherited disorders.
Harvard University1, Cleveland Clinic2, University of Minnesota3, Fred Hutchinson Cancer Research Center4, University of Texas MD Anderson Cancer Center5, Shaare Zedek Medical Center6, University of Manitoba7, University of Chicago8, Memorial Sloan Kettering Cancer Center9, Greenville Health System10, University of Texas Southwestern Medical Center11, Stanford University12, Sheba Medical Center13, Vanderbilt University Medical Center14
TL;DR: The role of hematopoietic cell transplantation for adults with acute lymphoblastic leukemia (ALL) is reviewed and critically evaluated and standard indications as well as the areas of controversy are summarized.
Cleveland Clinic1, Ottawa Hospital Research Institute2, Fred Hutchinson Cancer Research Center3, University of Colorado Denver4, National Institutes of Health5, Stanford University6, Imperial College London7, Center for International Blood and Marrow Transplant Research8, Duke University9, Vanderbilt University Medical Center10, University of Calgary11
TL;DR: Based on the available evidence, the ASBMT recommends that treatment-refractory relapsing MS with high risk of future disability be considered a "standard of care, clinical evidence available" indication for AHCT.
TL;DR: The data indicate that patients with higher baseline disease burden have more severe CRS, and that CAR-T cell therapy is associated with lymphoma pseudoprogression and local immune activation.
TL;DR: Corticosteroid-refractory graft-versus-host disease (SR-GVHD) remains a significant source of morbidity after allogeneic hematopoietic cell transplantation, and the role of continuing prophylactic antimicrobial measures in ruxolitinib-treated GVHD patients is supported.
TL;DR: The data support the use of ruxolitinib for cGVHD refractory to steroids and currently available salvage therapies, discontinued due to lack of response and high cost.
TL;DR: An electronic survey on the current administrative, logistic, and toxicity management practices of CAR T cell therapy across the United States is conducted to gain insight into the infrastructure and practices across the country.
University of Texas MD Anderson Cancer Center1, National Institutes of Health2, Medical College of Wisconsin3, Center for International Blood and Marrow Transplant Research4, University of Southern California5, Children's Hospital Los Angeles6, University of Bern7, Emory University8, University of Iowa Hospitals and Clinics9, Johns Hopkins University10, City of Hope National Medical Center11, Loyola University Chicago12, Mayo Clinic13, West Virginia University14, Georgetown University15, University of Florida16, Memorial Sloan Kettering Cancer Center17, Harvard University18, Vanderbilt University Medical Center19, Dokkyo Medical University20, Seattle Cancer Care Alliance21, University of Maryland, Baltimore22
TL;DR: Haplo/PTCy-based approaches are associated with lower incidences of cGVHD and relapse, with PFS and OS outcomes comparable with MSD/CNI-based approach.
Guy's and St Thomas' NHS Foundation Trust1, Imperial College London2, Geneva College3, Charité4, University of Freiburg5, Heidelberg University6, University of Tübingen7, University of Cambridge8, University of Münster9, University Medical Center Utrecht10, Lille University of Science and Technology11
TL;DR: It is suggested that MAC should still be used for younger individuals suitable for such an approach due to a trend towards less relapse and an overall suggested advantage of improved GRFS; albeit this should be examined in a more homogeneous cohort.
TL;DR: Patients ≥ 70 years of age had worse outcome except for those with active AML, according to a multivariate analysis of reduced intensity conditioning in older patients with acute myeloid leukemia.
TL;DR: In patients with R/R ALL, InO followed by allogeneic HSCT provided an optimal long-term survival benefit among those with no previous HSCT who went directly to transplant after remission.
TL;DR: In this pretreated, high-risk population, clinically meaningful benefit and an acceptable safety profile was observed with additional follow-up for ibrutinib, demonstrating a substantial advance in the therapeutic management of patients with cGVHD.
TL;DR: This manuscript reviews possible mechanisms of treatment failures and, based on the timing of relapse, considers potential salvage therapies and opportunities for future clinical studies.
TL;DR: High-risk cytogenetics is frequently observed in newly diagnosed myeloma with extramedullary disease and significantly worsens outcome after single autologueous while tandem autologous transplant strategy may overcome onset poor prognosis.
TL;DR: This review provides an overview of the incorporation of PROs in CAR-T cell therapy and the specific challenges in this context and recommends frequent monitoring ofPROs in the first year to identify potential late effects like cognitive deficit or autoimmune manifestations.
TL;DR: Most recipients of haplo PBT develop CRS, but less than 20% experience severe complications, and the development of severe CRS significantly increases NRM.
TL;DR: Evaluated the off-label use of vedolizumab, a gut-selective immunomodulator, for treating steroid-refractory gastrointestinal (GI) acute GVHD (aGVHD) in patients with hematologic malignancies and found an overall response rate of 64%, overall survival (OS), and serious adverse effects (SAEs) of 54%.
TL;DR: The data suggest that blinatumomab is an effective salvage therapy in this patient population of adults with relapsed/refractory acute lymphoblastic leukemia following allogeneic hematopoietic stem cell transplantation (alloHSCT).
TL;DR: It is concluded that TA-TMA is a heterogenous disease that occurs after allogeneic transplantation and management with immunosuppressant withdrawal does not impact patient outcomes, and management of TA- TMA should focus on the treatment of underlying diseases.